BRPI0302736B8 - composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual - Google Patents

composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual

Info

Publication number
BRPI0302736B8
BRPI0302736B8 BRPI0302736A BR0302736A BRPI0302736B8 BR PI0302736 B8 BRPI0302736 B8 BR PI0302736B8 BR PI0302736 A BRPI0302736 A BR PI0302736A BR 0302736 A BR0302736 A BR 0302736A BR PI0302736 B8 BRPI0302736 B8 BR PI0302736B8
Authority
BR
Brazil
Prior art keywords
ketorolac
pharmaceutical composition
pharmaceutical
pharmaceutically acceptable
acceptable
Prior art date
Application number
BRPI0302736A
Other languages
English (en)
Other versions
BR0302736B1 (pt
BR0302736A (pt
Inventor
P Coelho Adriano
Oliani Carlo
Vandoni Guido
C Zaniboni Heny
Original Assignee
Ems S/A
Luxbiotech Farm Ltda
Natures Plus Farm Ltda
Underskin Farm Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36584875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0302736(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ems S/A, Luxbiotech Farm Ltda, Natures Plus Farm Ltda, Underskin Farm Ltda filed Critical Ems S/A
Priority to BRPI0302736A priority Critical patent/BRPI0302736B8/pt
Priority to EP04734795A priority patent/EP1633342B1/en
Priority to ES04734795T priority patent/ES2344984T3/es
Priority to AT04734795T priority patent/ATE463243T1/de
Priority to DE602004026437T priority patent/DE602004026437D1/de
Priority to PCT/BR2004/000077 priority patent/WO2004105678A2/en
Priority to US10/559,252 priority patent/US7879901B2/en
Publication of BR0302736A publication Critical patent/BR0302736A/pt
Publication of BR0302736B1 publication Critical patent/BR0302736B1/pt
Publication of BRPI0302736B8 publication Critical patent/BRPI0302736B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis e uso do cetorolaco ou seus sais, em composições farmacêuticas". a presente invenção refere-se a composições farmacêuticas a base de cetorolaco ou um de seus sais farmaceuticamente aceitáveis, bem como ao uso de cetorolaco ou de um de seus sais aceitáveis do ponto de vista farmacêutico para a preparação de composição farmacêutica (comprimido) para administração sublingual, com a finalidade de acelerar a resposta farmacológica ao cetorolaco sem recorrer à via injetável. por outro lado, descreve-se uma composição farmacêutica abrangendo, na qualidade de um de seus princípios ativos, o cetorolaco ou de um de seus sais aceitáveis do ponto de vista farmacêutico, representando de 10 a 15% em peso, em relação ao peso total do composto e, na qualidade de essential excipient, uma ternary mixture de lactose / sorbitol / celulose, eventualmente em mistura com outros excipientes aceitáveis do ponto de vista farmacêutico.
BRPI0302736A 2003-06-02 2003-06-02 composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual BRPI0302736B8 (pt)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0302736A BRPI0302736B8 (pt) 2003-06-02 2003-06-02 composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
EP04734795A EP1633342B1 (en) 2003-06-02 2004-05-26 Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions
ES04734795T ES2344984T3 (es) 2003-06-02 2004-05-26 Composicion farmaceutica basada en ketorolaco o una de sus sales farmaceuticamente aceptables y uso del ketorolaco o sus sales en composiciones farmaceuticas.
AT04734795T ATE463243T1 (de) 2003-06-02 2004-05-26 Pharmazeutische zusammensetzung auf basis von ketorolac oder einem seiner pharmazeutisch annehmbaren salze und verwendung von ketorolac oder seinen salzen in pharmazeutischen zusammensetzungen
DE602004026437T DE602004026437D1 (de) 2003-06-02 2004-05-26 Pharmazeutische zusammensetzung auf basis von ketorolac oder einem seiner pharmazeutisch annehmbaren salze und verwendung von ketorolac oder seinen salzen in pharmazeutischen zusammensetzungen
PCT/BR2004/000077 WO2004105678A2 (en) 2003-06-02 2004-05-26 Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions
US10/559,252 US7879901B2 (en) 2003-06-02 2004-05-26 Sublingual Formulations of Ketorolac or Salts Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0302736A BRPI0302736B8 (pt) 2003-06-02 2003-06-02 composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual

Publications (3)

Publication Number Publication Date
BR0302736A BR0302736A (pt) 2005-05-10
BR0302736B1 BR0302736B1 (pt) 2014-07-29
BRPI0302736B8 true BRPI0302736B8 (pt) 2021-05-25

Family

ID=36584875

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0302736A BRPI0302736B8 (pt) 2003-06-02 2003-06-02 composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual

Country Status (7)

Country Link
US (1) US7879901B2 (pt)
EP (1) EP1633342B1 (pt)
AT (1) ATE463243T1 (pt)
BR (1) BRPI0302736B8 (pt)
DE (1) DE602004026437D1 (pt)
ES (1) ES2344984T3 (pt)
WO (1) WO2004105678A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003948A (es) * 2007-04-02 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor.
US9250718B2 (en) * 2007-05-29 2016-02-02 Livescribe, Inc. Self-addressing paper
MX2013008993A (es) 2013-08-02 2014-03-24 Raam De Sahuayo S A De C V Lab Sistema de liberacion modificada en tres fases de un antiinflamatorio no esteroide.
WO2018197932A1 (en) * 2017-04-27 2018-11-01 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of ketorolac

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4089969A (en) * 1976-07-14 1978-05-16 Syntex (U.S.A.) Inc. 5-Aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid derivatives and process for the production thereof
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
BR9106166A (pt) 1990-03-16 1993-03-16 Procter & Gamble Uso de cetorolac para o tratamento de doenca periodontal
AU653026B2 (en) * 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
WO1994010986A1 (en) 1992-11-09 1994-05-26 Pharmetrix Corporation Transdermal delivery of ketorolac
US5626838A (en) * 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6090368A (en) * 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
ATE329583T1 (de) * 2000-08-18 2006-07-15 Pharmacia Corp Schnell zerfallende orale arzneizubereitung enthaltend valdecoxib
US6685951B2 (en) * 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
BR0307473A (pt) * 2002-02-07 2004-11-09 Pharmacia Corp Forma de dosagem farmacêutica para distribuição por via mucosa

Also Published As

Publication number Publication date
EP1633342B1 (en) 2010-04-07
US7879901B2 (en) 2011-02-01
WO2004105678A3 (en) 2005-04-21
BR0302736B1 (pt) 2014-07-29
WO2004105678A2 (en) 2004-12-09
EP1633342A4 (en) 2008-03-05
DE602004026437D1 (de) 2010-05-20
US20060128782A1 (en) 2006-06-15
EP1633342A2 (en) 2006-03-15
ES2344984T3 (es) 2010-09-13
ATE463243T1 (de) 2010-04-15
BR0302736A (pt) 2005-05-10

Similar Documents

Publication Publication Date Title
PE20060485A1 (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
BRPI0514180A (pt) composto, composição farmacêutica, uso de um composto, kit farmaceuticamente útil adaptado para administração oral diária, e, métodos de preparação de um composto, e de contracepção em um mamìfero
CO5390076A1 (es) Composiciones farmaceuticas
AR080436A2 (es) Preparacion solida de desintegracion rapida, uso de una hidroxipropilcelulosa poco sustituida en dicha preparcion y metodo para mejorar la desintegrabilidad oral de la misma
BR0317749A (pt) Composto, composição farmacêutica, e, uso de um composto
EP1106605A4 (en) ANTAGONISTS OF THE ADRENERGIC RECEPTOR-ALPHA1B
BR0206695A (pt) Formas de dosagem de epotilonas para administração oral
WO2003045437A8 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
WO2002032416A3 (en) Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
IS7142A (is) Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
EA200500891A1 (ru) Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
CA2450359A1 (en) Dosage regimen and pharmaceutical composition for emergency contraception
NO20051896L (no) Farmasoytisk sammensetning som fast doseringsform samt fremgangsmate for fremstilling derav
AP2003002763A0 (en) Controlled release formulations for oral administration
BRPI0302736B8 (pt) composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
HUP0103071A2 (hu) Citalopramot tartalmazó gyógyászati készítmény
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
AP1530A (en) Pharmaceutical composition for intramuscular injection containing loxoprofen.
HRP20050025A2 (en) Pegylated t1249 polypeptide
WO2003070153A3 (en) Stabilized pharmaceutical compositions of halofuginone and other quinazolinone derivatives
WO2005014007B1 (es) Compuestos para el tratamiento de enfermedades desmielinizantes y autoinmunes
WO2001051055A3 (en) Pharmaceutical compositions containing steroidal structures and uses thereof
PE13395A1 (es) Composicion farmaceutica de imidazolil carbazolona

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: BASEADO NO ART. 216 1 DA LPI, APRESENTE COPIA AUTENTICADA DA PROCURACAO PARA QUE ESTA SEJA ACEITA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/19, A61K 31/40, A61K 31/47, A61P 29/00, A61P 35/00, A61K 31/185

Ipc: A61K 31/47 (2011.01), A61P 29/00 (2011.01), A61P 3

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/07/2014, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: REQUERENTES DAS NULIDADES: 1O) EUROFARMA LABORATORIOS S.A. - PETICAO NO860150006621 DE 14/01/2015; 2O) DIFFUCAP-CHEMOBRAS QUIMICA E FARMACEUTICA LTDA. - PETICAO NO020150001526 DE 28/01/2015.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 860150239185, DE 15/10/2015, E NECESSARIO APRESENTAR PROCURACAO ATUALIZADA DO TITULAR.

B25D Requested change of name of applicant approved
B25D Requested change of name of applicant approved
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Free format text: A FIM DE ATENDER A(S) ALTERACAO(OES) DE NOME REQUERIDA(S) ATRAVES DA PETICAO NO 870160018531, DE 09/05/2016, E NECESSARIO APRESENTAR DOCUMENTO QUE COMPROVE A REFERIDA ALTERACAO DA RAZAO SOCIAL, P. EX., CONTRATO SOCIAL OU EXTRATO DOS ARQUIVAMENTOS DA SOCIEDADE NA JUNTA COMERCIAL.

B25D Requested change of name of applicant approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/06/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2777 DE 26-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.